Compare · NVOS vs TMO
NVOS vs TMO
Side-by-side comparison of Novo Integrated Sciences Inc. (NVOS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVOS and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $176.13B, about 5031.9x NVOS ($35.0M).
- TMO has hit the wire 19 times in the past 4 weeks while NVOS has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for NVOS).
- Company
- Novo Integrated Sciences Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.15-17.66%
- $473.94-1.69%
- Market cap
- $35.0M
- $176.13B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 19
- Recent ratings
- 0
- 25
Novo Integrated Sciences Inc.
Novo Integrated Sciences, Inc., together with its subsidiaries, provides primary healthcare services. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations. In addition, the company offers specialty treatment and recovery programs derived from motor vehicle accident injuries, long-term disability cases, corporate wellness, and job-site injuries. Further, it provides cold laser therapeutics, shockwave therapy, custom bracing and orthotics, custom compression therapy/stockings, and lymphatic drainage treatment. The company offers medical technology services, such as telemedicine and remote patient monitoring. It operates 16 owned clinics, a contracted network of 102 affiliate clinics, and 220 eldercare related care homes, as well as retirement homes and community-based locations in Canada. The company was incorporated in 2000 and is based in Bellevue, Washington. Novo Integrated Sciences, Inc. is a subsidiary of ALMC-ASAP Holdings, Inc.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest NVOS
- SEC Form SEC STAFF ACTION filed by Novo Integrated Sciences Inc.
- Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update
- Novo Integrated Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update
- Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update
- Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update
- Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update
- SEC Form NT 10-Q filed by Novo Integrated Sciences Inc.
- SEC Form 10-K filed by Novo Integrated Sciences Inc.
- Novo Integrated Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)